Clinical Trials
3 trialsNCT07071961 2026-06-05
Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]
M.D. Anderson Cancer Center
Phase 2 Suspended
NCT05064059 2026-05-26
MK-4280A-007
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04787341 2026-05-20
PARERE
Gruppo Oncologico del Nord-Ovest
Phase 2 Active not recruiting